# Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

> **NCT06427083** · — · ACTIVE_NOT_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 200 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Envlo Tablet
- **DRUG:** Envolomet SR Tablet

## Key facts

- **NCT ID:** NCT06427083
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427083, "Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06427083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*